<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03771820</url>
  </required_header>
  <id_info>
    <org_study_id>NC-6004-009</org_study_id>
    <nct_id>NCT03771820</nct_id>
  </id_info>
  <brief_title>Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen</brief_title>
  <official_title>Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoCarrier Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orient Europharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NanoCarrier Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended&#xD;
      Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or&#xD;
      metastatic squamous cell carcinoma of the head and neck who have failed platinum or a&#xD;
      platinum containing regimen.&#xD;
&#xD;
      In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab&#xD;
      versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose&#xD;
      identified in PIIa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Recommended Phase (RPII) dose (mg/m2) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>In PIIa portion, to determine RPII dose of NC-6004 in combination with pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare median Progression Free Survival (PFS) between NC-6004 +pembrolizumab and pembrolizumab alone</measure>
    <time_frame>1 year</time_frame>
    <description>In PIIb portion, to compare PFS between NC-6004 plus pembrolizumab and pembrolizumab alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare median Overall Survival (OS) between NC-6004 +pembrolizumab and pembrolizumab alone</measure>
    <time_frame>2 years</time_frame>
    <description>In PIIb portion, to compare OS rate between NC-6004 plus pembrolizumab and pembrolizumab alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall response (complete response and partial response) rate between NC-6004 +pembrolizumab and pembrolizumab alone</measure>
    <time_frame>1 year</time_frame>
    <description>In PIIb portion, to ORR between NC-6004 plus pembrolizumab and pembrolizumab alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare duration of response between NC-6004 +pembrolizumab and pembrolizumab alone</measure>
    <time_frame>1 year</time_frame>
    <description>In PIIb portion, to compare DOR between NC-6004 plus pembrolizumab and pembrolizumab alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare time to response between NC-6004 +pembrolizumab and pembrolizumab alone</measure>
    <time_frame>1 year</time_frame>
    <description>In PIIb portion, to compare TTR between NC-6004 plus pembrolizumab and pembrolizumab alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by severity of Adverse Events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>The safety endpoints for this study are the incidence and severity of AEs in accordance with the NCI CTCAE and the occurrence of SAEs and treatment discontinuations due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Maximum Plasma Concentration (Cmax) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of the Maximum Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Time to Maximum Concentration (Tmax) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of Time to Maximum Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Area Under the Concentration (AUC) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of Area Under the Concentration (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Half-life(T½) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of Half-life(T½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Clearance (CL) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Volume of Distribution (V) of NC-6004 in combination with pembrolizumab</measure>
    <time_frame>1 year</time_frame>
    <description>Assess PK parameters of Volume of Distribution (V)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>SCCHN</condition>
  <arm_group>
    <arm_group_label>NC-6004 +pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.&#xD;
In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-6004</intervention_name>
    <description>NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.</description>
    <arm_group_label>NC-6004 +pembrolizumab</arm_group_label>
    <other_name>Nanoplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.</description>
    <arm_group_label>NC-6004 +pembrolizumab</arm_group_label>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          -  Males or females aged ≥18 years at screening.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Have histologically- or cytologically-confirmed HNSCC.&#xD;
&#xD;
          -  Have recurrent disease not amenable to curative treatment with local or systemic&#xD;
             therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx,&#xD;
             hypopharynx, or larynx that is considered incurable by local therapies.&#xD;
&#xD;
          -  Having prior platinum failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary&#xD;
             origination, squamous cell carcinoma that originates from the skin and salivary gland&#xD;
             or paranasal sinus, nonsquamous histologies.&#xD;
&#xD;
          -  Have disease that is suitable for locoregional treatment administered with curative&#xD;
             intent or refuses curative intent.&#xD;
&#xD;
          -  Have no more than 15% body weight loss due to the underlying condition in the last 3&#xD;
             months from signing of informed consent in Part 1 of the study and from randomization&#xD;
             in to Part 2.&#xD;
&#xD;
          -  Are currently participating in or have participated in a study of an investigational&#xD;
             agent or are using an investigational device within 4 weeks prior to the first dose of&#xD;
             trial treatment.&#xD;
&#xD;
          -  Were previously treated with 3 or more lines of systemic therapies administered for&#xD;
             recurrent and/or metastatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsushi Osada</last_name>
    <role>Study Director</role>
    <affiliation>NanoCarrier US LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atsushi Osada</last_name>
    <phone>781 219 4958</phone>
    <email>osada@nanocarrier.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>0603</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0601</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0602</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0701</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0702</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0703</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0104</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0105</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0103</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0101</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0202</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0201</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0801</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0802</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0301</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0303</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0301</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0404</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0402</name>
      <address>
        <city>Taipei city</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0403</name>
      <address>
        <city>Taipei city</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0401</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0902</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0903</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>0904</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

